Is azole resistance in aspergillus fumigatus a problem in Spain?

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2815-2820

  Escribano, Pilar ^a,b,c   Peláez, Teresa ^a,b,c,d   Munoz, Patricia ^a,b,c,d   Bouza, Emilio ^a,b,c,d   Guinea, Jesús ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; ITRACONAZOLE; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOMA; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS LENTULUS; ASPERGILLUS NOVOFUMIGATUS; ASPERGILLUS VIRIDINUTANS; CONTROLLED STUDY; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NEOSARTORYA; NEOSARTORYA UDAGAWAE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGAL PROTEINS; HOSPITALS, TEACHING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; SPAIN; TUBULIN;

EID: 84877871670     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02487-12     Document Type: Article

References (53)

1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50:1091-1100.
2. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48:265-273.
3. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, Pfaller M, Steinbach WJ, Webster KM, Marr KA. 2010. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl. Infect. Dis. 12:220-229.
4. Denning DW. 2006. Aspergillus and aspergillosis-progress on many fronts. Med. Mycol. 44(Suppl.):1.
5. Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. 2010. Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. Haematologica 95:644-650.
6. Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, Bouza E. 2010. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome. Clin. Microbiol. Infect. 16:870-877.
7. Singh N, Husain S. 2009. Invasive aspergillosis in solid organ transplant recipients. Am. J. Transplant 9(Suppl. 4):S180-S191.
8. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
9. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
10. Guinea J, Peláez T, Alcalá L, Ruiz-Serrano MJ, Bouza E. 2005. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: Analysis by site of isolation. Antimicrob. Agents Chemother. 49:3495-3497.
11. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
12. Cuenca-Estrella M, Gómez-López A, Mellado E, Buitrago MJ, Monzón A, Rodríguez-Tudela JL. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
13. Peláez T, Alvarez-Pérez S, Mellado E, Serrano D, Valerio M, Blanco JL, García ME, Muñoz P, Cuenca-Estrella M, Bouza E. 2013. Invasive aspergillosis caused by cryptic Aspergillus species: A report of two consecutive episodes in a patient with leukemia. J. Med. Microbiol. 62:474-478.
14. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. 2010. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
15. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. 2005. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot. Cell 4:625-632.
16. Díaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodríguez- Tudela JL. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
17. Mellado E, García-Effrón G, Alcázar-Fuoli L, Cuenca-Estrella M, Rodríguez-Tudela JL. 2004. Substitutions at methionine 220 in the 14alphasterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750.
18. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453.
19. Mellado E, García-Effrón G, Alcázar-Fuoli L, Melchers WJ, Verweij PE, Cuenca-Estrella M, Rodríguez-Tudela JL. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
20. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ. 2012. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: A case study and review of the literature. Antimicrob. Agents Chemother. 56:10-16.
21. Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung RT. 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48:197-200.
22. Kuipers S, Bruggemann RJ, de Sevaux RG, Heesakkers JP, Melchers WJ, Mouton JW, Verweij PE. 2011. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob. Agents Chemother. 55:3564-3566.
23. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
24. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
25. Snelders E, Huis in 't Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75:4053-4057.
26. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
27. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, Denning DW. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
28. Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, Bretagne S, Miegeville M, Le Pape P. 2012. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J. Antimicrob. Chemother. 67:1870-1873.
29. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE. 2011. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17:1846-1854.
30. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67:362-366.
31. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46: 1813-1821.
32. Bulpa P, Dive A, Sibille Y. 2007. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 30: 782-800.
33. Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, Guarro J, Haase G, Kibbler CC, Meyer W, O'Donnell K, Petti CA, Rodríguez-Tudela JL, Sutton D, Velegraki A, Wickes BL. 2009. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: Where are we and where should we go from here? J. Clin. Microbiol. 47:877-884.
34. Staab JF, Balajee SA, Marr KA. 2009. Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J. Clin. Microbiol. 47:2079-2083.
35. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
36. Verweij PE, Howard SJ, Melchers WJ, Denning DW. 2009. Azoleresistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
37. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Espinel-Ingroff A, Fowler CL, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Sheehan DJ, Walsh TJ. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
38. Espinel-Ingroff A, Diekema DJ, Fothergill A, Johnson E, Peláez T, Pfaller MA, Rinaldi MG, Cantón E, Turnidge J. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
39. Escribano P, Recio S, Peláez T, Bouza E, Guinea J. 2011. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob. Agents Chemother. 55:2460-2462.
40. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect. Dis. 9:789-795.
41. Alanio A, Sitterle E, Liance M, Farrugia C, Foulet F, Botterel F, Hicheri Y, Cordonnier C, Costa JM, Bretagne S. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66: 371-374.
42. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, Mihara T, Hosogaya N, Takazono T, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Nishino T, Tsukamoto M, Kakeya H, Yamamoto Y, Yanagihara K, Yasuoka A, Tashiro T, Kohno S. 2012. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob. Agents Chemother. 56:584-587.
43. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55:4465-4468.
44. Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, Howard SJ, Arendrup MC. 2011. A prospective survey of Aspergillus spp. in respiratory tract samples: Prevalence, clinical impact and antifungal susceptibility. Eur. J. Clin. Microbiol. Infect. Dis. 30:1355-1363.
45. Chryssanthou E. 1997. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand. J. Infect. Dis. 29:509-512.
46. Warris A, Klaassen CH, Meis JF, De Ruiter MT, De Valk HA, Abrahamsen TG, Gaustad P, Verweij PE. 2003. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J. Clin. Microbiol. 41: 4101-4106.
47. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. 2012. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob. Agents Chemother. 56:6060-6061.
48. Peláez T, Gijón P, Bunsow E, Bouza E, Sánchez-Yebra W, Valerio M, Gama B, Cuenca-Estrella M, Mellado E. 2012. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. J. Clin. Microbiol. 50:2531-2534.
49. Mortensen KL, Jensen RH, Johansen HK, Skov M, Pressler T, Howard SJ, Leatherbarrow H, Mellado E, Arendrup MC. 2011. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: A laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 49:2243-2251.
50. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, Honore I, Dupouy-Camet J, Dusser D, Klaassen CH, Meis JF, Hubert D, Paugam A. 2012. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56:869-874.
51. Mortensen KL, Mellado E, Lass-Florl C, Rodríguez-Tudela JL, Johansen HK, Arendrup MC. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549.
52. Escribano P, Recio S, Peláez T, González-Rivera M, Bouza E, Guinea J. 2012. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: Presence of heteroresistant populations. Antimicrob. Agents Chemother. 56:174-178.
53. Denning DW, Park S, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, Smith J, Bueid A, Moore CB, Bowyer P, Perlin DS. 2011. Highfrequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52: 1123-1129.